

8 April 2024

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description	Nature of dealings	Purchase /	Total	Total amount	Highest (H)	Lowest (L)
		of relevant		Sale	number	paid / received	prices paid	prices paid
		securities			of shares		/ received	/ received
					involved			
CICC	2 April 2024	Other types	Closing / flattening / unwinding of	Sale	167,500	\$2,977,370.6200	\$17.7753	\$17.7753
Wealth		of securities	proprietary positions arising from					
Investment		(e.g. equity	unsolicited client-driven dealings.					
Limited		swaps)	I confirm this was done no later					
			than the close of the morning					
			trading session on the trading day					
			following the orginating					
			client-driven dealing					



Other types	Closing / flattening / unwinding of	Purchase	167,500	\$2,976,729.6000	\$17.7715	\$17.7715
of securities	proprietary positions arising from					
(e.g. equity	unsolicited client-driven dealings.					
swaps)	I confirm this was done no later					
	than the close of the morning					
	trading session on the trading day					
	following the orginating					
	client-driven dealing					

End

Note:

CICC Wealth Investment Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

CICC Wealth Investment Limited is ultimately owned by China International Capital Corporation Limited.

This revised form supersedes the form dated 3 April 2024.